Skip to main content

Table 4 (A) Analysis of median of overall survival received interventions (BCc1nanomedicine or placebo) and chemotherapy simultaneously. (B) Death rate analysis received interventions (BCc1nanomedicine or placebo) and chemotherapy simultaneously

From: A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients

Group Metastatic Non- metastatic
Total number BCc1(n = 14) Placebo (n = 19) BCc1(n = 12) Placebo (n = 20)
(A) Median of overall survival analysis
Median (days) 302 107 482 265
Std. error 133.23 55.09 a 27.769
Median 95% CI (lower) 40.87 0 a 210.573
Median 95% CI (upper) 563.13 214.98 a 319.427
P-value for test of equality of survival distributions 0.306 0.019
HRb
(BCc1/Placebo)
0.589 0.019
Stage (n)
 I 0 0 0 0
 II 0 0 0 3
 III 0 0 11 10
 IIII 14 19 0 0
(B) Death rate analysis
Death rate (%) 50 53 0 35
  1. Test of equality of survival distributions (for Bcc1 and placebo groups) assay with Log Rank (Mantel-Cox)
  2. aNo statistics are computed because all cases are censored
  3. bUnivariate cox regression model